Next Science Company Description

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand.

It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds.

The company was founded in 2012 and is headquartered in Sydney, Australia.

Next Science Limited

Country	Australia
Founded	2012
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Harry Hall

Contact Details

Address: Australia Square Sydney, 2000 Australia
Phone	61 4 1229 2977
Website	nextscience.com

Stock Details

Ticker Symbol	NXS
Exchange	Australian Securities Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	AU0000041329
SIC Code	3842

Key Executives

Name	Position
Harry Thomas Hall	MD, Chief Executive Officer and Director
Dr. Matthew Franco Myntti	Founder and Chief Technology Officer
Marc Zimmerman	Chief Financial Officer
Jon Swanson	Chief Strategy Officer
Daniel Canon	Vice President of Operations
Francoise Dixon	Head of Investor Relations
Robert Bell	Senior Vice President of North American Sales
Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD	Company Secretary